Balyasny Asset Management
TGTX icon

Balyasny Asset Management’s TG Therapeutics TGTX Stock Holding History

Balyasny Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-31,200
Closed -$1.13M – 3555
2025
Q3 		$1.13M Buy
31,200
+4,500
+17% +$148K ﹤0.01% 2065
2025
Q2 		$961K Buy
26,700
+12,600
+89% +$469K ﹤0.01% 2048
2025
Q1 		$556K Buy
+14,100
New +$474K ﹤0.01% 2241

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Balyasny Asset Management's TGTX Position: Q4 2025 in Review

Balyasny Asset Management sold out of TG Therapeutics (TGTX) in Q4 2025, closing a stake of 183,823 shares — an estimated $6M sold.

Balyasny Asset Management first reported a position in TGTX in Q2 2018 and held it in 14 quarters. The position peaked at $25.1M in Q2 2025. 351 funds tracked by Wall St. Rank hold TGTX as of Q4 2025.

  • Balyasny Asset Management reported no remaining TG Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 183,823 TG Therapeutics shares in Q4 2025, an estimated $6M.
  • Balyasny Asset Management first reported a position in TG Therapeutics in Q2 2018 and held it in 14 quarters.
  • Balyasny Asset Management's TG Therapeutics position peaked at $25.1M in Q2 2025.
  • 351 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2025.

Based on Balyasny Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.